|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Chronic Obstructive Pulmonary Disease (COPD)
Two major diseases contribute to COPD: emphysema and chronic bronchitis. The chief symptoms are chronic cough, spitting or coughing up mucus (expectoration), breathlessness on exertion, and progressive reduction in the ability to breathe out fully. Cigarette smoking accounts for 82% of COPD deaths.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
COPD Study CNVA237A2303
The purpose of this clinical trial is to determine the long term benefits and safety of the investigative drug NVA237 as a once daily treatment in people with moderate to severe chronic obstructive pulmonary disease (COPD). “An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).”
Trial phase: Phase 3 Participation Duration: Participants in this study will be asked to visit the study center 18 times over a 1 year period. Protocol Number: CNVA237A2303 |